Stifel Nicolaus assumed coverage on shares of Chimerix (NASDAQ:CMRX) in a report issued on Thursday,TheFlyOnTheWall.com reports. The firm issued a buy rating and a $34.00 target price on the stock. Chimerix Inc (NASDAQ:CMRX) stock opened at $26.00 in last session, and closed at $27.14, while the day range of stock is $25.03 – $27.46.The stock showed a positive weekly performance of 44.90%.
Albany Molecular Research (NASDAQ:AMRI) was upgraded by equities research analysts at TheStreet from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Analyst Ratings.Net reports. Albany Molecular Research, Inc. (NASDAQ:AMRI) stock opened at $17.01, in last session and closed at $18.81, by gaining 9.49%. The 52 week range of the stock is $8.92 – $18.95. Company’s market capitalization is $594.35 million.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor Inc (NASDAQ:XNCR) stock advanced 1.61% and finished the last session at $13.90. The EPS of the stock remained 3.11. Company’s market capitalization is $380.76 million.
Fate Therapeutics, Inc. (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − P rohema in UM bilical cord blood transplant in A dults) on Prohema. Fate Therapeutics Inc (NASDAQ:FATE) stock opened the session at $8.85, and closed the session at $11.15. The 52 week range of the stock remained $4.30 – $12.81 and the day range was $8.70 – $12.81.
Leave a Reply